Is TVTX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The FSGS launch, a market with no prior approved therapy, with revenue (ttm) at ~$591M, up ~77% year over year. The bear case rests on single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment. Analysts covering it are spread from $43.00 to $75.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $43.00, -31.5% from the $62.76 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The FSGS launch, a market with no prior approved therapy. FSGS is the second indication and the cleaner competitive setup, because until April 2026 no drug was approved for it at all. The most optimistic analyst target on TVTX is $75.00, +19.5% from the $62.76 price. That figure is only reachable if this thesis works close to its best case.

Single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment. The IgA nephropathy field got crowded quickly, with Novartis marketing both VANRAFIA (atrasentan) and FABHALTA (iptacopan), Otsuka selling TARPEYO and Voyxact, and Vera Therapeutics winning approval for Trutakna (atacicept), and FILSPARI carries a REMS program and a boxed warning for hepatotoxicity and embryo-fetal toxicity that at least one rival endothelin blocker does not. Regulatory timing has already proven volatile for this stock: shares fell more than 30% in January 2026 when the FDA extended the FSGS review, and several plaintiff law firms opened securities investigations afterward, though the application was subsequently approved. The balance sheet carries more debt (~$617 million, largely convertible) than cash (~$489 million), so continued losses would eventually mean dilution or refinancing. Finally, pegtibatinase data is more than a year out, which leaves little to cushion a disappointment in the commercial franchise before then. The most pessimistic published target is $43.00, -31.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Travere Therapeutics develops and sells treatments for rare kidney and metabolic diseases, with FILSPARI for IgA nephropathy and FSGS as its lead commercial product.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The FSGS launch, a market with no prior approved therapy) stalling in the reported numbers rather than in the narrative, the risk above (single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Travere is a commercial-stage biopharmaceutical company focused on rare kidney and metabolic diseases. It sells FILSPARI (sparsentan) for IgA nephropathy and focal segmental glomerulosclerosis, and THIOLA and THIOLA EC (tiopronin) for cystinuria. It also runs a clinical pipeline led by pegtibatinase for classical homocystinuria.

The overwhelming majority. In Q2 2026, FILSPARI US net sales were ~$141.1 million out of ~$169.6 million in total revenue, or roughly 83%. That share has been rising as FILSPARI grows and the legacy THIOLA franchise stays flat, which makes TVTX effectively a single-product story.

Not yet on a GAAP basis. Trailing twelve-month net income was ~-$43 million, and Q2 2026 showed a ~$34.8 million net loss (~$9.0 million on a non-GAAP adjusted basis). Trailing free cash flow has turned positive at ~$93 million, so the gap between reported losses and actual cash generation is narrowing.